interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Abaloparatide

Generic competition · all medicines · read 12 November 2026

Is there a generic of Abaloparatide, and who makes it?

Abaloparatide appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Abaloparatide1 dosage-form group in the Orange Book
0generic makers listed
  1. Abaloparatide appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Solution, Subcutaneous

Brand listed, no generic listed as marketed

Brand listed as marketed: Tymlos. No generic is listed as marketed.

20152020202520302035204001brand 2017data datePatent 8748382 listed to expire 3 October 2027Patent 8148333 listed to expire 8 November 2027Patent 7803770 listed to expire 28 April 2031Patent RE49444 listed to expire 28 April 2031Patent 11782041 listed to expire 30 April 2038Patent 11977067 listed to expire 30 April 2038Patent 10996208 listed to expire 30 April 2038Patent 11680942 listed to expire 10 January 2040Patent 11255842 listed to expire 10 January 2040
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 3 October 2027Patent 8748382
  • 8 November 2027Patent 8148333 drug product
  • 28 April 2031Patent 7803770
  • 28 April 2031Patent RE49444
  • 30 April 2038Patent 11782041 drug product
  • 30 April 2038Patent 11977067 drug product
  • 30 April 2038Patent 10996208 drug product
  • 10 January 2040Patent 11680942

1 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.